That is what I am most curious to hear about is the NIH tier 3 preclinical progress. I think it is a pretty big deal and will decide the fate of when/if this company moves forward on the other development programs. My opinion is it could prove their pain/epilepsy candidate to be extremely valuable leading to a big BP deal and NIH grant funding or just somewhat valuable or not valuable at all, although I think there has been enough success to indicate some value along some paths. Maybe too this is why not bothering with 10-k, 10-q currently?
No idea how long those trials take. What I could find implied maybe a few months for the animal testing part, but who knows what prep, post and follow-up work is included. I am long for the boom or bust of it all. Judging by the filings, so are most of the insiders, institutional investor types associated. Could be many moons away before we hear anything or really could be anytime too. Patiently waiting.
News 
Market Data 
Discover 
